News coverage about Glaukos Corporation (NYSE:GKOS) has been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Glaukos Corporation earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the medical instruments supplier an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an effect on the company’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern’s scoring:
- Shares Running on Volume: Glaukos Corp (GKOS) – Stock Press Daily (stockpressdaily.com)
- Total System Services Inc (nolopodrasdejardever.com)
- Glaukos Corporation (GKOS) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com)
- Wimbledon 2017: Venus Williams looking to strike for old brigade (cromaplus.net)
- Piedmont Office Realty Trust, Inc. (NYSE:PDM) Valuation According To Analysts (nolopodrasdejardever.com)
Shares of Glaukos Corporation (GKOS) opened at 40.12 on Tuesday. Glaukos Corporation has a one year low of $28.26 and a one year high of $52.49. The company’s 50 day moving average price is $40.47 and its 200 day moving average price is $42.42. The firm has a market capitalization of $1.38 billion, a P/E ratio of 364.73 and a beta of 1.33.
Several equities analysts have recently weighed in on GKOS shares. Zacks Investment Research lowered shares of Glaukos Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $54.00 target price on shares of Glaukos Corporation in a research note on Thursday, May 4th. TheStreet cut shares of Glaukos Corporation from a “c” rating to a “d+” rating in a research report on Wednesday, May 3rd. Stephens raised shares of Glaukos Corporation from an “equal weight” rating to an “overweight” rating in a research report on Monday, May 8th. Finally, BMO Capital Markets reissued a “buy” rating and set a $54.00 price target on shares of Glaukos Corporation in a research report on Tuesday, April 11th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $48.50.
ILLEGAL ACTIVITY NOTICE: This report was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://transcriptdaily.com/2017/07/18/glaukos-corporation-gkos-earns-daily-news-sentiment-score-of-0-16-updated-updated-updated.html.
Glaukos Corporation Company Profile
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.